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Different members of intracellular protein families are recognized by the immune system
of the vertebrate host infected by parasites of the genus Leishmania. Here, we have
analyzed the antigenic and immunogenic properties of the Leishmania eIF2 and eIF2B
translation initiation factors. An in silico search in Leishmania infantum sequence
databases allowed the identification of the genes encoding the α, β, and γ subunits
and the α, β, and δ subunits of the putative Leishmania orthologs of the eukaryotic
initiation factors F2 (LieIF2) or F2B (LieIF2B), respectively. The antigenicity of these factors
was analyzed by ELISA using recombinant versions of the different subunits. Antibodies
against the different LieIF2 and LieIF2B subunits were found in the sera from human and
canine visceral leishmaniasis patients, and also in the sera from hamsters experimentally
infected with L. infantum. In L. infantum (BALB/c) and Leishmania major (BALB/c or
C57BL/6) challenged mice, a moderate humoral response against these protein factors
was detected. Remarkably, these proteins elicited an IL-10 production by splenocytes
derived from infected mice independently of the Leishmania species employed for
experimental challenge. When DNA vaccines based on the expression of the LieIF2 or
LieIF2B subunit encoding genes were administered in mice, an antigen-specific secretion
of IFN-γ and IL-10 cytokines was observed. Furthermore, a partial protection against
murine CL development due to L. major infection was generated in the vaccinated
mice. Also, in this work we show that the LieIF2α subunit and the LieIF2Bβ and δ
subunits have the capacity to stimulate IL-10 secretion by spleen cells from naïve
mice. B-lymphocytes were identified as the major producers of this anti-inflammatory
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cytokine. Taking into account the data found in this study, it may be hypothesized that
these proteins act as virulence factors implicated in the induction of humoral responses
as well as in the production of the down-regulatory IL-10 cytokine, favoring a pathological
outcome. Therefore, these proteins might be considered markers of disease.
Keywords: Leishmania, antigens, interleukin-10, visceral leishmaniasis, translation initiation factors, experimental
murine models, vaccines
INTRODUCTION
Leishmaniases comprise a complex group of diseases caused
by the infection of protozoa of the genus Leishmania.
These parasites multiply as intracellular amastigotes within
macrophages of their vertebrate hosts and as extracellular
promastigotes in the gut of the insect vector (phlebotomine
sand flies) (Dostálová and Volf, 2012). The parasite species as
well as the immune-competence state of the host determine
disease spectrum. Cutaneous leishmaniasis (CL) is the less severe
form of the disease. It is caused by infection, among other
species, with Leishmania major in the OldWorld and Leishmania
braziliensis in the New World. Visceral leishmaniasis (VL) is
characterized by parasite dispersion to internal organs causing
a form of the disease that results deadly if treatment is not
administered (Rodrigues et al., 2016). It has been estimated
that there are 20,000–40,000 deaths per year due to VL in the
less protected regions of the world (Alvar et al., 2012). The
parasite invades the patient internal organs causing episodes
of fever, weight loss, anemia, and swelling of the spleen and
the liver (Herwaldt, 1999; Torres-Guerrero et al., 2017). In the
Mediterranean countries, Middle-East, Asia, and South America,
VL it is caused by Leishmania infantum [synonym Leishmania
chagasi (Maurício et al., 2000)]. Wild canids and domestic dogs
are the major reservoir of these parasites playing a central
role in the transmission to humans by phlebotomine sand flies
(Palatnik-de-Sousa and Day, 2011; Esch and Petersen, 2013). The
infection in dogs also causes a severe form of VL complicated
with different cutaneous manifestations (CanVL) (Baneth et al.,
2008; Solano-Gallego et al., 2011, 2017; Abbehusen et al., 2017).
For both mammalian hosts, after infection some individuals can
remain asymptomatic mainly because of the induction of Th1
cellular responses and IFN-γ mediated macrophage activation
for destruction of intracellular parasites. On the other hand,
the symptomatic forms of the disease are associated with the
generation of IL-4 mediated humoral responses against parasite
antigens and an IL-10 dependent inhibition of macrophage
activation (Murray, 1997; Miles et al., 2005; Baneth et al., 2008).
Visceral leishmaniasis patients possess antibodies recognizing
different parasite antigens including surface molecules, some
secreted factors and different intracellular proteins belonging to
evolutionary conserved families that play essential cell functions.
These families comprise tubulins (Abanades et al., 2012), heat
shock proteins (Quijada et al., 1996, 1998), histones (Soto et al.,
1999; Maalej et al., 2003), or PUF proteins (Folgueira et al., 2010).
Some of these proteins families are also antigenic in CL patients
(Rafati et al., 2007; Souza et al., 2013; Duarte et al., 2015). The
presence of high titers of anti-Leishmania antibodies is thought to
be linked with pathology due to the adverse effects of deposition
of the immune complexes in different tissues (García-Alonso
et al., 1996; Jain et al., 2000). Moreover, the presence of IgG
immune complexes correlates to the down regulation of IL-12
production and the secretion of IL-10 by macrophages in mice
infected with L. major and in human VL patients (Miles et al.,
2005) depending on the density of the IgG complexes formed
(Gallo et al., 2010). In addition, most of these antigens are able to
induce cellular responses in CL and VL human patients or dogs
affected by CanVL (Probst et al., 2001; Rafati et al., 2007; Carrillo
et al., 2008; Meddeb-Garnaoui et al., 2010; Baharia et al., 2014).
During the last few years, attention has been focused on
translation initiation process in Leishmania, since it has emerged
as an important point of regulation of gene expression in these
parasites (Requena, 2012). In a recent work, the parasite eIF5A
has been studied at the molecular level, although its function
in Leishmania still remains unknown (Singh et al., 2014).
Studies performed with the components of the Leishmania eIF4F
complex (eIF4A, eIF4E, and eIF4G) (Yoffe et al., 2004, 2006,
2009; Pereira et al., 2013) and poly (A)-binding proteins (PABPs)
(da Costa Lima et al., 2010) have demonstrated that translation
initiation in Leishmania, as occurs in the rest of eukaryotes,
depends on the interaction with the 5′ CAP structure and
poly(A) tails present in the mRNAs. Similarly, the identification
of functional domains in the different subunits of Leishmania
eIF3 complex suggests a conserved mechanism in translation
initiation in Leishmania (Rezende et al., 2014). Little is known
about the components and functions of the heterotrimeric eIF2
factor in Leishmania. This factor has a GTP binding activity
and it is implicated in the formation of the ternary complex
that recruits the Met-tRNA to the small subunit of the ribosome
for translation initiation. To be functional, the participation
of the multi-subunit eIF2B complex is required. This guanine
exchange factor is responsible for the GDP-GTP recycling of
eIF2 (Hinnebusch, 2014). In Leishmania, phosphorylation of
the eIF2α subunit inhibits GTP recycling inducing the down
regulation of global translation occurring during promastigote
to amastigote differentiation (Chow et al., 2011; Cloutier et al.,
2012).
Protein factors implicated in the translation process in
Leishmania also play relevant roles regarding parasite persistence
in the vertebrate host. This is the case for the Leishmania α-
subunit of the elongation factor-1 complex (EF-1), involved
in regulating the rate and fidelity of protein translation.
Remarkably, this factor is able to interact and activate
the macrophage tyrosine phosphatase-1 (SHP-1) resulting in
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macrophage deactivation and parasite survival within this cell
type (Nandan et al., 2002). The recognition of some other parasite
proteins implicated in translation by the host immune system has
been also demonstrated. In this regard, the parasite PABPs have
been found to be antigenic proteins in canine and human VL
patients and humans affected by mucocutaneous leishmaniasis
(MCL) due to L. braziliensis infection (Guerra et al., 2011; Soto
et al., 2015). In addition, the L. braziliensis initiation factor
5a (LbeIF5A) is an antigenic protein recognized by the sera
from human patients infected with L. braziliensis (Duarte et al.,
2015). To date, the eIF4A is the most studied parasite translation
initiation factor because of its relation with the host immune
system. This protein seems to help the host for fighting against
infection, since it was described as an inductor of Th1 mediated
responses after infection in human patients (Skeiky et al., 1995)
and in experimental murine models of infection (Skeiky et al.,
1998). Remarkably, it is also able to activate macrophages
for controlling parasite replication by the induction of pro-
inflammatory cytokines (Probst et al., 1997; Koutsoni et al.,
2014). Importantly, experimental vaccines based on the PABPs
(Soto et al., 2015) or LeIF4A, either alone (Skeiky et al., 1998) or
fused with other parasite antigens forming a recombinant poly-
protein (Coler et al., 2002, 2007; Bertholet et al., 2009), have
the potential of inducing protection against the infection with
different Leishmania species. Similarly, a recombinant version
of the LbeIF5a factor was able to induce protection against
L. infantum (Duarte et al., 2016a) and Leishmania amazonensis
(Duarte et al., 2017) challenges when administered as part of a
polyprotein vaccine.
With the aim of exploring the antigenicity and prophylactic
properties of other Leishmania proteins involved in translation,
in this work we have worked with the L. infantum F2 (LieIF2)
and F2B (LieIF2B) proteins. With this purpose, the L. infantum
putative orthologs of the α-, β-, and γ-subunits of the eukaryotic
initiation factor eIF2 and the α-, β-, and δ subunits of the
eukaryotic factor eIF2B were produced as recombinant proteins
and tested in ELISA using human and canine VL sera. Given
that these initiation factors were found to be antigenic in natural
VL, analyses were extended to a highly susceptible experimental
model of VL, namely hamsters infected with L. infantum
(Requena et al., 2000b; Carrion et al., 2006). In addition, we
have analyzed the humoral and cellular responses elicited against
LieIF2 and LieF2B inmurinemodels of VL (L. infantum-BALB/c)
and CL: susceptible (L. major-BALB/c) or resistant (L. major-
C57BL/6). Finally, DNA vaccines based on both factors were
constructed and assayed in BALB/c and C57BL/6 CL mouse
models.
MATERIALS AND METHODS
Cloning of L. infantum eIF2 (LieIF2) and
eIF2B (LieIF2B) Factors Coding Regions
The DNA regions encoding the LieIF2α (LinJ.03.0960), LieIF2β
(LinJ.08.0570), LieIF2γ (LinJ.09.1130), LieIF2Bα (LinJ.12.0001),
LieIF2Bβ (LinJ.10.1030), and LieIF2Bδ (LinJ.27.1090) subunits
were rescued from the L. infantum genome database (www.
genedb.org) using the Saccharomyces cerevisiae (gene accession
numbers: YJR007W, 0YPL237W, YER025W, YKR026C,
YLR291C, YGR083, respectively) orthologous encoding
gene sequences as queries. Genomic DNA from L. infantum
(MCAN/ES/1996/BCN/150/MON-1) was employed as template
for PCR, since no introns are present in Leishmania DNA
(Requena, 2012). Primer sequences are available in the
Supplementary Table 1. The resultant PCR products were
cloned in the BamHI cut site of the pBluescript II SK vector
(Stratagene. CA, U.S.A). DNA inserts containing the coding
regions were obtained by BamHI digestion and subcloned in
the same cut site of the pcDNA3.1/N-HA (pcDNA) eukaryotic
expression vector (GenScript. NJ, U.S.A) for DNA vaccines, or
in the same site of the pQE30 prokaryotic expression vector
poly-linker (Qiagen, Hilden, Germany) for recombinant protein
production.
DNA Vaccines and Recombinant Proteins
Production
For DNA vaccine, the pcDNA clones were transformed in the
XL1-blue strain of Escherichia coli and grown. Plasmid DNA
extraction was performed with the Endofree plasmid Giga Kit
(Qiagen). The correct expression of the different DNA constructs
was analyzed by western-blot using an anti-HA antibody (Sigma,
MO, U.S.A) taking advantage of the presence of the HA tag in
the N-terminal region of the recombinant proteins. Samples were
obtained in COS-7 cells transfected with plasmid constructions
as described in Soto et al. (2015) but using an anti-mouse
IgG conjugated to horseradish peroxidase as secondary reagent
(Nordic Immunological Laboratories, Tilburg, The Netherlands).
E. coli M15 strain bacteria, transformed with the different
pQE30 recombinant plasmids were employed for obtaining the
Leishmania factors as recombinant proteins fused to an N-
terminal His-tag. After over-expression of proteins in IPTG-
induced cultures, the bacteria were centrifuged (5,000 × g) and
total protein extracts were solubilized in binding buffer (BB;
20mM Tris HCl pH 8.0, 0.5M NaCl, 5mM imidazole, 8M
urea, 1mM 2-mercaptoethanol). For ELISA, solubilized total
extracts were passed through a Ni-NTA affinity chromatography
resin. Next, the column was washed in BB containing up to
20mM imidazole. Finally, recombinant proteins were obtained
from the column by passing BB containing 0.5M imidazole. For
final preparation, dialysis of the purified proteins with ELISA
denaturant coating buffer was performed (EDCB: 3Murea, 0.5M
NaCl, 5mM imidazol, 1mM 2-mercaptoethanol in 20mM Tris
HCl pH 8). In order to use the recombinant proteins as stimuli in
cell culture assays, protein extracts were resuspended in BB. After
binding to the Ni-NTA resin, interacting proteins were refolded
on the affinity column as described (Shi et al., 1997). After,
elution buffer was replaced by PBS using dialysis. To remove
endotoxin traces, affinity chromatography polymyxin-agarose
(Sigma) columns were employed. TheQuantitative Chromogenic
Limulus Amebocyte Assay QCL-1000 (BioWhittaker, MD,
U.S.A.) was used to determine the presence of lipopolysaccharide
(LPS). In all cases, proteins stocks presented <20 ng of LPS per
mg of recombinant protein. Freeze-thaw total parasite extracts,
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namely SLA (soluble Leishmania antigens), were prepared
as described elsewhere (Iborra et al., 2005). The Bio-Rad
Protein Bradford assay (Bio-Rad, CA, U.S.A.) was employed for
determination of protein concentrations.
Mice and Parasites
Female BALB/c and C57BL/6 mice (6–8 week old) were
purchased from Envigo (Barcelona, Spain). Two parasite species
were employed: L. infantum (MCAN/ES/96/BCN150) and
L. major [clone V1 (MHOM/IL/80(Friedlin)]. Promastigotes
were grown by culturing at 26◦C in M3 medium (Gibco,
BRL, Grand Island, NY, U.S.A) containing 10% heat inactivated
fetal calf serum (FCS) and 200 U/ml penicillin and 100µg/ml
streptomycin. L. major metacyclic promastigotes were isolated
from stationary cultures by negative selection using peanut
agglutinin (Vector Laboratories, Burlingame, CA, U.S.A). For
VL murine models, BALB/c mice were infected intravenously
(i.v.) with 5× 106 stationary-phase promastigotes of L. infantum
in the tail vein. For murine CL models, BALB/c or C57BL/6
mice were infected by an intradermal (i.d.) inoculation in
both ears with 1 × 103 metacyclic L. major promastigotes. In
some experiments, BALB/c mice were challenged subcutaneously
(s.c.) in the footpad with 1 × 105 L. major promastigotes at
the stationary-phase. All procedures were performed according
to the Directive 2010/63/UE from the European Union and
RD53/2103 from the Spanish Government. Procedures were
approved by the next agencies: Severo Ochoa Molecular Biology
Center Animal Care and Use Committee (CEEA-CBMSO
21/138), Bioethical Committee of the CSIC (under reference
100/2014), Government of the Autonomous Community of
Madrid (Spain PROEX121/14).
Sera Collections
Human anonymized sera samples were randomly selected from
human VL diagnosed patients stored in a serum bank (LIP-
CPqGM-FIOCRUZ) built from independent studies previously
conducted in Brazil in a VL endemic area (n = 20) (Abanades
et al., 2012). Canine symptomatic VL sera (n= 38) were collected
in the Extremadura region of Spain (previously described in
Coelho et al., 2009). The sera from healthy individuals [human
(n = 10); dogs (n = 13)] were also employed for comparative
analysis. A collection of sera from hamster obtained from
animals infected with 103 (n = 5) or 104 (n = 4) L. infantum
promastigotes by the intracardiac (i.c.) route, built from a
previous published study was also employed (Requena et al.,
2000b). All animals (n = 9) presented splenomegaly and
detectable parasite burdens in the spleen and liver at the end of
the assay. Sera were taken before challenge and from month 1 to
month 11 post-challenge. Serum samples from healthy hamsters
were employed as controls (n = 17). To analyze the antigenicity
of the translation initiation factors, murine sera collection was
obtained from BALB/c mice i.v. challenged with L. infantum
(n = 8) and sera from BALB/c (n = 8) s.c. challenged with
L. major in the left footpad, or C57BL/6 mice (n = 8) i.d.
challenge with the same parasite species in both ears. All sera
were taken at week 8 after challenge. Sera taken from the same
mice before infection were employed as negative controls. Sera
from the four different mammalian species present a positive
reaction against SLA (Supplementary Figure 1).
ELISA Assays
The ELISAs were performed onMaxiSorp plates (Nunc, Roskilde,
Denmark). For coating, 0.2 µg per well of the recombinant
proteins (in EDCB) or 1 µg per well of SLA (in PBS) were
overnight incubated at 4◦C. Next, four washes with PBS plus
0.5% Tween 20 (PBS-Tw) were performed. For blocking, PBS-
Tw buffer supplemented with 5% non-fat milk was employed [1 h
at room temperature (RT)]. For the analyses of IgG responses,
human, canine, hamster, or mouse sera were assayed for 2 h at
RT (1/100 dilution in the same buffer employed for blocking).
Four washes with PBS-Tw were performed before incubation
with secondary antibodies conjugated to horseradish peroxidase
(1/2,000 dilution in the blocking solution for 1 h at RT). The
following antibodies, obtained from Nordic (Nordic BioSite,
Täby, Sweden) were employed: anti-dog IgG, anti-human IgG,
anti-hamster IgG. Finally, after four washes in PBS-Tw the TMB
ELISA substrate solution was employed for reaction developing.
After incubation for 15min in the dark, reaction was stopped
by addition of 2N H2SO4. Optical densities (O.D.) were read at
450 nm in an ELISA microplate spectrophotometer (Bio-Rad).
For murine samples, the IgG1 (BALB/c and C57BL6), IgG2a
(BALB/c), and IgG2c (C57BL/6) antigen-specific titers were
determined by ELISA following the same procedure except that
serial dilutions (1/2 dilution factor) of the sera were performed.
Anti-mouse IgG1, IgG2a, and IgG2c antibodies horseradish
peroxidase conjugated were employed as secondary reagents
(Nordic). Sera reactivity was determined as the reciprocal end-
point titer calculated as the inverse value of the highest serum
dilution factor giving an absorbance value above that of the
pre-immune sera.
Analysis of the Cellular Immune Responses
For the analysis of cytokine responses, the spleens of the
mice were individually processed by mechanical homogenization
in complete RPMI medium (RPMI medium supplemented
with 10% heat-inactivated FCS, 20mM L-glutamine, 200 U/ml
penicillin, and 100µg/ml streptomycin) and splenocytes passed
through a cell strainer (70-µm pore size). Afterwards, cells
were cultured in RPMI complete medium at 5 × 106 cells
per ml at 37◦C in 5% CO2 alone or stimulated with either
SLA or either LieIF2α, LieIF2β, LieIF2γ, LieIF2Bα, LieIF2Bβ,
or LieIF2Bδ recombinant proteins (all of them at 12µg/ml
final concentration) for 72 h. In some experiments, a mix of
the LieIF2 subunits or a mix of the LieIF2B subunits were
employed (12µg/ml final concentration; 4µg/ml each subunit).
The levels of IFN-γ, IL-10, or IL-4 were determined in culture
supernatants by sandwich ELISA using monoclonal antibodies
specific for mouse cytokines (capture and detection) provided in
commercial kits (Pharmingen, San Diego, CA, U.S.A), following
the manufacturer’s instructions.
For the analysis of IL-10 production in naïve mice, spleen
cultures established from BALB/c and C57BL/6 mice were
cultured for 48 h in RPMI complete medium at 37◦C in 5%
CO2 with 12µg/ml of either recombinant proteins (LieIF2α,
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LieIF2β, LieIF2γ, LieIF2Bα, LieIF2Bβ, or LieIF2Bδ), LPS (0.1,
1, or 10 ng/ml) or medium alone. The presence of IL-10 was
determined in culture supernatants as indicated above. To
identify the cells producing IL-10, equivalent cultures were
prepared and stimulated. For the last 6 h BD GolgiStop protein
transport inhibitor was added to the cultures. Afterwards, cells
were harvested, washed twice in PBS with 1% FCS (PBS-St)
and incubated with Mouse Fc Block prior to surface staining.
Cells were then stained with fluorochrome-conjugated antibodies
against B220 AlexaFluor 647 or CD3 AlexaFluor 647 and isotype-
specific control antibodies for 30min on ice. Cells were washed
twice with PBS-St and fixed for 20min in Cytofix/Cytoperm.
Next, cells were washed in PermWash Buffer and incubated
with PE-conjugated anti mouse IL-10 for 30min at 4◦C. Finally,
cells were washed twice and data were collected and analyzed
using a FACSCanto II Cytometer and FlowJo 10.0.7 software.
All reagents and antibodies used in the cytometric assays were
purchased from BD Biosciences (Franklin Lakes, NJ, U.S.A).
Vaccination, Clinical Follow-Up, and
Parasite Loads
Mice (BALB/c and C57BL/6) were s.c. inoculated in the right
footpad three times, 2 weeks apart, with 200 µg of the following
preparations: empty pcDNA3 (200 µg), a mixture of pcDNAs
containing the genes encoding LieIF2 subunits (LieIF2α, LieIF2β,
and LieIF2γ; 67 µg each) or a mixture of of pcDNAs containing
the genes encoding LieIF2B subunits (LieIF2Bα, LieIF2Bβ, and
LieIF2Bδ, 67 µg each) prepared in PBS. As an additional control,
a group of mice received the same volume (30 µl) of the vaccine
diluent. For both mouse strains, animals (n = 8 per group)
were euthanized at the time of infection to analyze the immune
response elicited by vaccination. Parasite challenge was carried
out at the fourth week after vaccination s.c. in the left footpad of
the BALB/c mice or i.d. in the ear dermis of both BALB/c and
C57BL/6 mouse strains with the doses depicted above (section
Mice and Parasites). For the analysis of the clinical signs of
infection, the footpad swelling (thickness of the infected left
footpad minus thickness of the right footpad) or the diameter
of the ear lesions was weekly measured with a metric caliper.
BALB/c mice s.c. infected in the footpad were euthanized at
week 8 post-challenge (n = 8). The BALB/c mice i.d. infected
in the ear dermis were euthanized at week 5 (n =5) and at
week 8 (n = 5), whereas C57BL/6 mice were euthanized at
week 5 (n = 5) and at week 9 post-challenge (n = 5). For
parasite load determination, the popliteal lymph nodes (LNs)
draining the footpad (for s.c. infected animals), the ears, the
retromandibular draining LNs and the spleen of eachmouse were
individually taken and mechanically homogenized in Schneider’s
complete medium (Schneider’s medium supplemented with
20% heat-inactivated FCS, 200 U/ml penicillin, and 100µg/ml
streptomycin). Ear sheets were previously digested for 2 h at 37◦C
in Dulbecco’s modified Eagle medium containing Liberase TL
enzyme (50µg/ml; Roche Diagnostics, Mannheim, Germany).
Samples were serially diluted (1/3) in Schneider’s complete
medium and plated on triplicates in a 96-well plates. The number
of viable parasites was calculated from the highest dilution at
which promastigotes could be grown with up to 10 days of
incubation at 26◦C (Buffet et al., 1995).
Statistical Analysis
Statistical analyses were performed using the Graph-Pad Prism
Program. A D’Agostino and Pearson test was employed to
analyze the Gaussian distribution of the samples when n ≥ 8.
The ELISAs cut-off values were calculated by comparison of
the reactivity values from infected and healthy groups using a
Receiver Operating Characteristic (ROC) analysis and defined
as the lowest O.D. value with a 100% of specificity. The Mann-
Whitney or the Kruskal-Wallis (followed by Dunn’s multiple
comparison analysis) tests were employed for analyzing two or
more samples, respectively. Significant differences was indicated
as ∗, +, x for P-value lower than 0.05, ∗∗, ++, xx for P-value lower
than 0.01 or ∗∗∗∗, +++, xxx for P value lower than 0.001.
RESULTS
Identification of Leishmania infantum eIF2
and eIF2B Factors
The genes encoding L. infantum eIF2 (LieIF2) and eIF2B
(LieIF2B) factors were identified in the sequence database of
L. infantum (www.genedb.org) by BLAST searches employing
the S. cerevisiae orthologs sequences. We retrieved the entries
annotated as the putative α, β, and γ subunits of the LieIF2
and α, β, and δ subunits of the LieIF2B complexes. As it is
shown in Table 1, the high degree of conservation found for
these proteins among different Leishmania spp. decreases when
they are compared to their putative orthologs in yeast (the
species selected for in silico search) and humans (one of the
mammalian hosts of the parasite). To get additional evidence
about the identity of the rescued proteins, an in silico search
for conserved domains was performed (http://www.ebi.ac.uk/
interpro/). It was found that the L. infantum subunits of both
complexes possess equivalent structural domains to those present
in the human ones, including the GTP binding domain located at
the amino-terminal region of the eIF2-γ subunit (Pain, 1996).
TABLE 1 | Amino acid sequence comparison analysis.
Leishmania
infantum
Leishmania
major
Saccharomyces
cerevisiae
Homo
sapiens
LieIF2α 98.6 (99.3) 34.8 (58.4) 31.0 (51.1)
LieIF2β 99.1 (99.7) 25.6 (45.8) 25.8 (41.8)
LieIF2γ 99.6 (99.6) 50.3 (69.9) 53.5 (72.0)
LieIF2Bα 97.7 (98.7) 24.1 (43.3) 27.9 (49.0)
LieIF2Bβ 97.4 (97.9) 23.2 (36.6) 24.7 (37.4)
LieIF2Bδ 96.2 (97.7) 23.3 (40.9) 25.0 (41.1)
The percentages of identity (similarity) are shown, obtained using the “water” tool of the
EMBOSS suite of bioinformatics. L. infantum and yeast gene accession numbers are
included in the Materials and Methods section. L. major genes accession numbers are:
LmjF.03.0980, LmjF.08.0550, LmjF.09.1070 LmjF.12.0010, LmjF.10.0950, LmjF.27.1210.
Human NCBI reference sequence entries are: NP_004085.1, NP_003899.2,
NP_001406.1, NP_001405.1, NP_055054.1, NP_001029288.1.
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Antigenicity of Leishmania infantum eIF2
and eIF2B Factors in Natural and
Experimental VL
We produced the six indicated subunits of the LieIF2 and
LieIF2B translation factors in E. coli and the resulting
His-tagged recombinant proteins were purified by affinity
chromatography. Firstly, we analyzed their antigenicity by
ELISA using different sera collections. The recognition of
sera collected from VL Brazilian human patients ranged
from 85.0% for LieIF2α to 20.0% for LieIF2Bα. Data were
summarized in Table 2 and the details regarding the sera
reactivity, determination of the cut-off values and the statistical
analysis were included in Supplementary Figure 2A. The
antigenicity of the subunits in the canine form of the
disease was also demonstrated, ranging the percentages of
positive samples between 73.7% for LieIF2γ and LieIF2Bβ
to 57.9% for LieIF2α and LieIF2Bα (Table 2; Supplementary
Figure 2B).
Next, we extended the studies to an experimental model of
the VL disease, namely hamster experimentally infected with
L. infantum. Eleven months after challenge, all the infected
animals had circulating antibodies against the subunits of
the LieIF2 and LieIF2B complexes (Table 2; Supplementary
Figure 2C). Additionally, in L. infantum-infected hamsters,
we studied the time course of appearance of anti-LieIF2
and anti-LieIF2B antibodies in parallel to anti-SLA along the
infection. With this purpose, hamster sera samples were collected
monthly after L. infantum challenge and analyzed by ELISA.
A continuous increase in the reactivity against either LieIF2
or LieIF2B subunits was observed from the first month post-
infection reaching the highest reactivity value at the end of
the assay, following a similar kinetics to the SLA recognition
(Figure 1).
Immune Responses Elicited Against the
LieIF2 and LieIF2B Subunits in Murine
Models of VL and CL
To further analyze the antigenic properties of the LieIF2 and
LieIF2B translation factors we take advantage of the high amino
acid sequence identity shared between the orthologous subunits
from L. infantum and L. major (Table 1).We studied the humoral
TABLE 2 | Percentages of sera positive for Leishmania eIF2 and eIF2B subunits.
Protein Human VL Canine VL Hamster VL
LieIF2α 85.0 57.9 100
LieIF2β 45.0 65.8 100
LieIF2γ 60.0 73.7 100
LieIF2Bα 20.0 57.9 100
LieIF2Bβ 50.0 73.7 100
LieIF2Bδ 80.0 71.1 100
Human (n= 20), canine (n= 38), and hamster (n= 9) sera were assayed by ELISA against
the different subunits, obtained as recombinant proteins.
and cellular responses elicited against the recombinant versions
of these subunits using sera samples as well as spleen cells from
BALB/cmice infected either with L. infantum (VLmurinemodel)
or with L. major (CL susceptible model). Samples from C57BL/6
mice infected with L. major were also analyzed (CL resistant
model). A moderate humoral response was found against the
LieIF2 and LieIF2B factors in these animals. All the subunits
were recognized by the sera from infected mice with percentages
ranging from 62.5 to 100% (Table 3 and Supplementary Figures
3A–C).
As occurs for anti-SLA antibodies (Supplementary Figure
4A) the immunoglobulins recognizing the six subunits were
predominantly of the IgG1 subclass in L. major infected BALB/c
mice (Figure 2A). In C57BL/6 mice a weak IgG2c predominant
response against the different subunits was observed (Figure 2B).
A mixed IgG1/IgG2a response against all the subunits was
observed in L. infantum infected BALB/c mice with the exception
of LieIF2γ that was predominantly recognized by IgG1 antibodies
(Figure 2C).
The analysis of the cytokine secretion after in vitro stimulation
of spleen cells from infected mice with the recombinant
subunits revealed a predominant IL-10 mediated response
in all experimental murine models. For the three LieIF2
(Figures 3A–C) and LieIF2B (Figures 3A–C) subunits, the
levels of IL-10 in culture supernatants were significantly
higher than the other two assayed cytokines (IFN-γ and IL-
4), with the exceptions of LieIF2β and LieIF2γ factors in
the VL model (Figure 3A). The levels of IFN-γ detected in
the supernatants of spleen cell cultures stimulated with the
recombinant factors were always lower than IL-10 amounts
(Figures 3A–C) contrasting with the parasite specific IFN-γ
predominant response observed when the same cells were
stimulated with SLA especially in VL and CL resistant models
(Supplementary Figure 4B).
Administration of the LieIF2 and LieIF2B
Subunits as DNA Vaccines Induces a
Partial Protection Against CL in Both
Susceptible and Resistant Murine Models
Given the remarkable antigenicity of these Leishmania proteins
in different hosts, we analyzed their immunogenicity when
administered as genetic vaccines (injection of naked DNA
eukaryotic expression plasmids). The correct expression of
the different plasmid constructs was demonstrated by western
blot using total protein extracts from COS cells transfected
with the plasmid collection (Figure 4A). Proteins bands of
expected sizes were recognized by an antibody specific for
the HA tag located in the N-terminal of the recombinant
Leishmania subunits produced in the mammalian cells
(Figure 4B).
Two different DNA vaccines were assayed: the LieIF2 vaccine,
composed by the same amounts of plasmids encoding the
LieIF2α, LieIF2β, and LieIF2γ subunits, and the LieIF2B vaccine,
containing the same amounts of the plasmids encoding the
LieIF2Bα, LieIF2Bβ, and LieIF2Bδ factors. To characterize
the immune response elicited by the vaccines, spleen cells
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FIGURE 1 | Time course of anti-leishmanial humoral response in infected hamsters. The presence of antibodies against the subunits of the LieIF2 factor (α, β, and γ),
the LieIF2B factor (α, β, and δ) or SLA was determined by ELISA using the sera from nine hamster infected by the intracardiac route with L. infantum promastigotes.
Sera were collected before challenge and monthly after infection until month 11th. Whisker (min to max) plots were employed to show the relative absorbance of the
sera (= absorbance values of a given serum obtained from an infected hamster divided by the absorbance value of the pre-immune sera from the same animal).
TABLE 3 | Percentages of murine sera positive for Leishmania eIF2 and eIF2B
subunits.
Protein VL CL susceptible CL resistant
LieIF2α 87.5 75 87.5
LieIF2β 87.5 87.5 100
LieIF2γ 100 100 75
LieIF2Bα 87.5 100 62.5
LieIF2Bβ 87.5 87.5 87.5
LieIF2Bδ 62.5 100 100
Sera (n = 8 per group) from BALB/c mice infected with L. infantum (VL) or L. major
(CL susceptible) and C57BL/6 infected with L. major were assayed by ELISA against
the different subunits, obtained as recombinant proteins.
from vaccinated and control mice (immunized with the saline
excipient or the non-recombinant plasmid) were cultured in
the presence or in the absence of a mixture of the subunits
composing each one of the vaccines. Administration of the
genetic vaccines either in BALB/c (Figures 5A,B) or in C57BL/6
mice (Figures 6A,B) resulted in the induction of both IFN-γ
and IL-10 mediated responses against LieIF2 or LiF2B subunits.
Remarkably, when cells of the two control mouse groups were
stimulated with a mixture of either the LieIF2 or LieIF2B
factors a specific IL-10 response was observed, although of
lesser magnitude regarding vaccinated groups (Figures 5, 6).
This comportment will be analyzed in more detail in the last
subsection of the results.
Additional immune-stimulation assays were done using
individual recombinant subunits instead of mixtures to in vitro
stimulate spleen cells from vaccinated mice. For BALB/c
mice, antigen-specific production of both IFN-γ and IL-
10 was elicited by all three LieF2 (Figure 7A) and LieIF2B
(Figure 7B) subunits, since we did not observe significant
differences in the levels of both cytokines for any of the
subunits. However, we detected a slight tendency to generate
higher levels of IL-10 by LieIF2α, LieIF2γ (Figure 7A), and
LieIF2Bα (Figure 7B) subunits, whereas LieIF2β (Figure 7A) and
LieIF2Bβ or LieIF2Bδ (Figure 7B) culture supernatants presented
a slight predominance of IFN-γ. In splenocytes from vaccinated
C57BL/6 mice, an antigen-specific production of IFN-γ and
IL-10 was also observed. In this mice strain, a predominant
IL-10 mediated response for all the subunits of the LieIF2
(Figure 8A) and LieIF2B (Figure 8B) factors was observed. This
was especially marked when the LieIF2α (Figure 8A) and the
LieIF2Bα (Figure 8B) subunits were employed as stimuli. In
these cultures the level of IL-10 was statistically incremented with
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FIGURE 2 | Analysis of the humoral response elicited against LieIF2 and LieIF2B in murine models of leishmaniasis. Mice (n = 8) per group were experimentally
challenged with L. major [susceptible BALB/c mice, CLs (A); resistant C57BL/6 mice, CLr (B)] or with L. infantum [BALB/c mice, VL(C)]. The IgG1 (BALB/c and
C57BL/6), IgG2a (BALB/c), or IgG2c (C57BL/6) titers against the indicated LieIF2 (left panels) and LieIF2B (right panels) subunits were determined by ELISA at week 8
post-challenge. Asterisks show the statistical differences between the indicated subclasses (Mann–Whitney test). Results in each panel are representative of two
independent experiments.
regard to the other studied cytokines. All the subunits stimulated
the production of very low levels of IL-4 in both mouse strains.
Finally, we tested the immune-prophylactic properties of these
DNA vaccines by challenging control and vaccinated mice with
L. major. For BALB/c mice, we firstly tested the effects of
vaccines in a model consisting in the inoculation of stationary-
phase promastigotes into the footpad. We observed that the
disease evolution of the LieIF2 vaccinated mice was slower
than in the control groups showing a significant decrease in
footpad swelling in the last 3 weeks of the assay (Figure 9A). In
addition, LieIF2 vaccinated mice showed a significant reduction
of the parasite burdens in the popliteal LN draining the infected
footpad with respect the burdens found in both control groups
(Figure 9B). Also, the parasite dispersion to internal organs,
measured as parasite load in the spleen, was very low in
the LieIF2 vaccinated mice in relation to that found for the
rest of the groups (Figure 9B). No significant differences in
disease evolution or parasite burdens were observed between
mice of the LieIF2B group and mice from both control groups
(Figures 9A,B).
We also analyzed the evolution of cutaneous lesions in control
and vaccinated animals after a challenge with highly infective
metacyclic promastigotes in the ear dermis of mice from the
BALB/c and C57BL/6 strains. In the BALB/c mice, LieIF2 and
LieIF2B vaccinated animals showed a slower evolution of the
lesions than the control groups that was more marked in
the LieIF2 group (Figure 9C). However, in any case, lesion
development was not contained and at the end of the study the
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FIGURE 3 | Analysis of the cellular response elicited against LieIF2 and LieIF2B in murine models of leishmaniasis. Mice (n = 8) per group were experimentally
challenged with L. infantum (BALB/c mice, VL) (A) or with L. major [susceptible BALB/c mice, CLs (B); resistent C57BL/6 mice, CLr (C)]. At week 8 post-challenge
spleen cells were prepared and cultured in the absence (Medium) or in the presence of the indicated LieIF2 and LieIF2B subunits. The presence of IFN-γ, IL-10, and
IL-4 cytokines in culture supernatants was measured by sandwich ELISA. The results are represented as Whisker (min to max) plots. Asterisks mark the statistical
differences among the three assayed cytokines (Kruskal–Wallis test). Results in each panel are representative of two independent experiments.
size of the lesions was similar in mice from vaccinated or control
groups. Local parasite loads mirrored lesion development. At
week 5 post-challenge, LieIF2 and LieIF2B vaccinated animals
showed a significant reduction of the parasite burdens in the
ears with respect to both control groups (Figure 9D). Regarding
the LN cells, only LieIF2 vaccinated mice showed lower number
of parasites than control groups (Figure 9D). However, as
occurred with the lesion size, at the end of the assay (8th
week after challenge) similar parasite loads were observed at
the ears and retromandibular LNs (Figure 9D). In addition,
LieIF2 and LieIF2B vaccinated animals present a remarkable
capacity to control Leishmania dispersion to internal organs
as revealed by the low number of parasites detected in their
spleens (Figure 9D). A partially protective effect of vaccination
was also observed in vaccinated C57BL/6 mice. Both LieIF2
and LieIF2B vaccinated mice developed lower ear lesions after
L. major inoculation than mice of control groups (Figure 9E).
Control in lesion development was correlated to the presence of
lower number of parasites in the ear and retromandibular LNs
5 weeks after challenge (Figure 9F, 5th week). At week 9 post-
challenge animals from the control groups still showed higher
parasite numbers than vaccinated animals (Figure 9F, 9th week).
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FIGURE 4 | Analysis of the expression of the DNA vaccines coding for the
LieIF2 and LieIF2B subunits. Untransfected COS7 (lane 1) as well as cells
transfected with pcDNA-HA (lane 2), pcDNA-HA-LieIF2α (lane 3),
pcDNA-HA-LieIF2β (lane 4), pcDNA-HA-LieIF2γ (lane 5), pcDNA-HA-LieIF2Bα
(lane 6), pcDNA-HA-LieIF2Bβ (lane 7), and pcDNA-HA-LieIF2Bδ (lane 8) for
72 h cells were harvested, lysed and separated on a 10% SDS-PAGE gel and
stained with Coomassie blue (A). A western blot performed with an equivalent
gel was incubated sequentially with an anti-HA antibody made in mouse and
an anti-mouse IgG antibody labeled with horseradish peroxidase and revealed
with 4-chloro-1-naphthol (B).
Analysis of the Implication of LieIF2 and
LieIF2B in the Induction of IL-10 Mediated
Responses in Naïve Mice
As it is shown in Figures 5, 6, stimulation of spleen cells from
either BALB/c or C57BL/6 control mice, receiving saline (or
empty pcDNA) in the immunization schedule, with a mixture
of LieIF2 (Figures 5A, 6A) or a mixture of LieIF2B (Figures 5B,
6B) subunits induced the production of moderate levels of IL-
10. To obtain more details about the subunits(s) responsible of
this effect, we processed the spleens from naïve mice (n= 6) and
the splenocytes were grown in the absence or in the individual
presence of the six subunits, monitoring the levels of IL-10
cytokine in the culture supernatants. The highest levels of IL-10
FIGURE 5 | Cytokine response induced by LieIF2 and LieIF2B-based genetic
vaccination in BALB/c mice. Three groups of BALB/c mice (n = 8 per group)
were inoculated with PBS (Saline group), with the pcDNA non-recombinant
vector (pcDNA group) of with a mixture of the pcDNA-LieIF2α + pcDNA-LiF2β
+ pcDNA-LieIF2γ plasmids (LieIF2 group) or alternatively, with a mixture of the
pcDNA-LieIF2Bα + pcDNA-LiF2Bβ + pcDNA-LieIF2δ plasmids (LieIF2B
group) three times, 2 weeks apart. Four weeks after the last dose, spleen cells
from mice of the saline, pcDNA and LieIF2 or LieIF2B vaccinated groups were
extracted and cultured in the presence or in the absence (Med), and a mixture
of the LieIF2 subunits (LieIF2α, LieIF2β, and LieIF2γ) for LieIF2 vaccinated mice
(A) or a mixture of the LieIF2B subunits (LieIF2Bα, LieIF2Bβ, and LieIF2δ) for
LieIF2B vaccinated animals (B). Graphs show the level of the indicated
cytokines in the cell culture supernatant determined by sandwich ELISA.
Results are presented as Whisker (min to max) plots. Asterisks show the
statistical differences between the level of cytokines in the supernatants of the
stimulated and the non -stimulated cultures (Mann–Whitney test), whereas the
+ or the X symbols show the statistical differences among saline and
vaccinated mice or pcDNA and vaccinated mice, respectively (Kruskal–Wallis
test).
were found after stimulation with the LieIF2α subunit, and the
three LieIF2B subunits in both BALB/c (Figure 10A) or C57BL/6
(Figure 10B) mice strains.
In a preliminary assay designed to analyze which cells
were responsible for the production of IL-10, parallel cultures
stimulated with these subunits, were analyzed by FACS to study
the percentages of IL-10+ B cells (B220+) or IL-10+ T cells
(CD3+). As it is shown in the Figure 10C, cultures stimulated
with the four subunits showed higher percentages of B220+IL-
10+ cells than the control unstimulated cultures, although
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FIGURE 6 | Cytokine response induced by LieIF2 and LieIF2B-based genetic
vaccination in C57BL/6 mice. Three groups of C57BL/6 mice (n = 8 per
group) were inoculated with PBS (Saline group), with de pcDNA
non-recombinant vector (pcDNA group) of with a mixture of the
pcDNA-LieIF2α + pcDNA-LiF2β + pcDNA-LieIF2γ plasmids (LieIF2 group) or
alternatively, with a mixture of the pcDNA-LieIF2Bα + pcDNA-LiF2Bβ +
pcDNA-LieIF2δ plasmids (LieIF2B group) three times, 2 weeks apart. Four
weeks after the last dose, spleen cells from mice of the saline, pcDNA and
LieIF2 or LieIF2B vaccinated groups were extracted and cultured in the
presence, or in the absence (Med), of a mixture of the LieIF2 subunits (LieIF2α,
LieIF2β, and LieIF2γ) for LieIF2 vaccinated mice (A) or a mixture of the LieIF2B
subunits (LieIF2Bα, LieIF2Bβ, and LieIF2δ) for LieIF2B vaccinated animals (B).
Graphs show the level of the indicated cytokines in the cell culture supernatant
determined by sandwich ELISA. Results are presented, as Whisker (min to
max) plots. Asterisks show the statistical differences between the level of
cytokines in the supernatants of the stimulated and the non-stimulated
cultures (Mann–Whitney test), whereas the + or the X symbols show the
statistical differences among saline and vaccinated mice or pcDNA and
vaccinated mice, respectively (Kruskal–Wallis test).
statistical significance was only attained in the cultures stimulated
with either LieIF2Bα or LieIF2Bβ subunits in both mouse strains;
Figure 10C shows the data and statistics and Supplementary
Figure 5A shows representative dot-plots. On the other hand, no
differences were found for CD3+IL10+ cells between stimulated
and unstimulated cultures (Figure 10D; Supplementary Figure
5B). As an additional control, stimulation of the splenocytes was
carried out in the presence of amounts of LPS similar (0.1 ng/ml)
and up to two orders of magnitude higher than those found in
the protein preparations. In these conditions, we detected low
levels of the cytokine in the supernatants (Supplementary Figure
5C). Moreover, no differences were found in the percentages
of B220+IL10+ cells between LPS stimulated or non-stimulated
cultures (Supplementary Figure 5D).
DISCUSSION
It is well-established that after Leishmania infection several
intracellular parasite proteins interact with the immune system
of the mammalian host. The existence of significant sequence
divergence for many intracellular conserved protein families
among Leishmania parasites and other eukaryotes is a common
feature that may be due to the ancient position of Leishmania
genus in the eukaryote phylogenetic tree (Sogin et al., 1986).
From an immunological point of view, the existence of these
differences is an important issue, since many of these protein
families are antigenic in human and canine VL patients and the
humoral and cellular responses are specific for parasite proteins
without cross-reactivity with the host counterparts (Soto et al.,
1999; Requena et al., 2000a; Maalej et al., 2003; Chenik et al.,
2006). The similarity values obtained for the LieIF2 and LieIF2B
subunits and their human orthologs range from 25 to 54%
(Table 1). These values were comparable to those reported for
other members of Leishmania translational machinery already
characterized: L. major eIF3 factor subunits (20–25%, Rezende
et al., 2014), Leishmania donovani eIF5A (45%, Singh et al.,
2014) or L. major eIF4F subunits, (eIF4E, 22%; eIF4A, 56%
and eIF4G, 25%, Dhalia et al., 2005). The data presented in
this work demonstrate that the LieIF2 and LieIF2B are humoral
markers of VL, since all the subunits were recognized by the
sera of human and canine patients. The variability observed
in the reactivity values found for each individual recombinant
subunit in both mammalian hosts suggests the existence of
individual differences in antigen recognition among human and
canine patients. A similar behavior was observed in other studies
performed with individual parasite antigenic proteins, assayed
with sera collections obtained from patients naturally infected
with the parasite in endemic areas (Soto et al., 1999; Maalej
et al., 2003; Goto et al., 2009). Comparison of the percentages of
positive individuals revealed important differences in the pattern
of recognition between both species (Table 2). In humans,
the LieIF2α subunit was the antigen recognized by a larger
number of sera, whereas LieIF2Bβ and LieIF2γ were the most
recognized by canine samples. Differences in canine and human
immune responses to these and other Leishmania antigens may
be reflecting differences in how the parasites interact with the
immune system of both hosts (Goto et al., 2009).
On the other hand, when an experimental model of VL
was employed, namely hamsters infected with L. infantum, we
observed a 100% of positivity (Table 2). The high percentage
value of antigenicity observed can be taken as an indication
that the degree of individual variability in the recognition of
both factors in this inbred experimental model is lower than
that existing in human and dog natural populations. However,
individual differences in the reactivity values of the hamster
sera persisted, since data followed non-parametric distributions
(Supplementary Figure 3C). Something similar occurred when
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FIGURE 7 | Cytokine response against LieIF2 and LieIF2B subunits in vaccinated BALB/c mice. Spleen cells cultures established from BALB/c mice vaccinated with
LieIF2 and LieIF2B genetic vaccines as indicated in the legend of Figure 5 were stimulated with the single LieIF2 subunits (LieIF2α, LieIF2β, and LieIF2γ) for LieIF2
vaccinated mice (A) or the single LieIF2B subunits (LieIF2Bα, LieIF2Bβ, and LieIF2δ) for LieIF2B vaccinated animals (B) or grown in medium alone. Graphs show the
level of the indicated cytokines in the cell culture supernatant determined by sandwich ELISA. Results are presented, as Whisker (min to max) plots. Asterisks mark
the statistical differences among the levels found in the culture supernatants of the three assayed cytokines (Kruskal–Wallis test). Results in each panel are
representative of two independent experiments.
FIGURE 8 | Cytokine response against LieIF2 and LieIF2B subunits in vaccinated C57BL/6 mice. Spleen cells cultures established from C57BL/6 mice vaccinated
with LieIF2 and LieIF2B genetic vaccines as indicated in the legend of Figure 6 were stimulated with the single LieIF2 subunits (LieIF2α, LieIF2β, and LieIF2γ) for
LieIF2 vaccinated mice (A) or the single LieIF2B subunits (LieIF2Bα, LieIF2Bβ, and LieIF2δ) for LieIF2B vaccinated animals (B) or grown in medium alone. Graphs show
the level of the indicated cytokines in the cell culture supernatant determined by sandwich ELISA. Results are presented, as Whisker (min to max) plots. Asterisks
mark the statistical differences among the levels found in the culture supernatants of the three assayed cytokines (Kruskal–Wallis test). Results in each panel are
representative of two independent experiments.
the sera samples employed in this work were assayed with
other antigenic proteins such as the surface protein KMP-11 or
intracellular antigens such as PUF proteins, the HSP20, HSP70,
and HSP83 stress proteins, the H2A and H3 histones or the
LiP2a and LiP2b acidic ribosomal proteins (Requena et al., 2000b;
Montalvo-Alvarez et al., 2008; Folgueira et al., 2010). Inclusion
of this experimental model in our work allowed us to make
a longitudinal analysis of the humoral response appearance.
Interestingly, similar profiles were observed for the anti-LieIF2
or anti-LieIF2B response and antibody generation against SLA
extracts, representing the whole parasite antigenic repertoire. A
continuous increase in the intensity of the response against the
factors and SLA found in this work (Figure 1) was concomitant
to the increase in the number of proteins recognized by the sera
of the hamster as shown previously (Requena et al., 2000b). At the
end of the study, most of the parasite proteins became antigenic,
being this observation in accordance with the induction of
exacerbated humoral responses during disease progression in
symptomatic VL human and canine patients (Miles et al., 2005;
Kumar and Nylén, 2012; Fernandez-Cotrina et al., 2013; Hasker
et al., 2014). It can be concluded then that the production of
antibodies against both factors occurs from the first moments
of infection. This demonstrates an early encounter between both
factors and the immunological system of the host and it is ruled
out that its antigenicity is due to the induction of the polyclonal
responses associated with the pathology of the VL (Deak et al.,
2010).
The intracellular location of the translation factors does not
seem to be an impediment for their antigenicity. Similarly, many
proteins with nuclear and cytosolic location, such as protein
related to the translational machinery, enzymes implicated in
parasite metabolism, heat shock proteins or histones have been
described as immunodominant antigens not only in human and
canine VL (Requena et al., 2000a; Coelho et al., 2009; Soto et al.,
2009, 2015; Ramírez et al., 2013; Baharia et al., 2014; Sundar and
Singh, 2014; Siripattanapipong et al., 2017), but also in human
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FIGURE 9 | Course of L. major infection in vaccinated mice. BALB/c (n = 18 per group) or C57BL/6 (n = 10 per group) were inoculated with saline, with pcDNA, with
the LieIF2 or with the LieIF2B genetic vaccines three times 2 weeks apart. Four weeks after the last inoculation mice were challenge with L. major, following the next
scheme: 5 × 105 stationary phase promastigotes in the footpad (BALB/c, n = 8 per group) or 1 × 103 metacyclic promastigotes in the dermis of both ears (BALB/c
and C57BL/6, n = 10 per group). In (A) the mean ± SD of the difference of thickness between the infected and the uninfected footpad (n = 8 mouse per group) is
represented. The asterisks symbolize the statistically decrease of footpad swelling of the LieIF2 vaccinated group with respect saline or pcDNA groups (Kruskal–Wallis
test). In (C) (BALB/c) and (E) (C57BL/6), the ear lesion diameter (mean ± SD) is shown (n = 20 ears from week 2 to week 5 post-challenge and n = 10 ears from
week 6 to the end of the assay). The statistically significant decrease of ear lesion found in LieIF2 (* asterisks) or in LieIF2B (+ symbol) vaccinated mice with respect
saline of pcDNA group is shown (Kruskal-Wallis test). In the three panels, and for simplicity, the lower value of significance found when data from vaccinated were
compared to saline and pcDNA control data is indicated in the graph. The number of viable parasites in the left popliteal LNs and spleens (BALB/c mice infected in the
footpad; B) , or the ears, the retromandibular LNs and the spleens in BALB/c (D) or C57BL/6 (F) mice challenged in the ear dermis were individually determined by
limiting dilution at the indicated weeks post-challenge. Mean ± SD of the log10 of the parasite burdens in the complete organs is shown. Asterisks represent the
significant differences between the indicated groups (Kruskal–Wallis test). In (B), biological samples from eight animals per group were employed. In (D,F), samples
from five animals were employed at the indicated times post-challenge. All the samples were processed individually.
CL patients havingmoderate anti-Leishmania humoral responses
(Ramírez et al., 2013; Souza et al., 2013; Duarte et al., 2015).
Interaction of these proteins with B lymphocytes for antibody
secretion may occur through complement mediated lysis of the
non-metacyclic parasites causing the release of the whole internal
cellular compounds (Mosser and Edelson, 1984; Ambrosio and
De Messias-Reason, 2005; Moreno et al., 2010). Also, non-
infective promastigotes can be lysed through the activity of
neutrophil extracellular traps although metacyclic promastigotes
are resistant to this innate immunity mechanism (Guimaraes-
Costa et al., 2009, 2014; Hurrell et al., 2016). The release of
different intracellular antigenic proteins contained in secreted
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FIGURE 10 | LieF2α, LieF2B β, and LieIF2δ subunits induce the secretion of IL-10 in B lymphocytes. Spleen cell cultures were established from naïve BALB/c or
C57BL/6 mice (n = 6 each strain). BALB/c (A) of C57BL/6 (B) cells were independently cultured without stimulus (Medium) or with the indicated recombinant
subunits. Graphs show the level of IL-10 culture supernatants. Frequencies of B220+ cells (C) of CD3+ cells (D) producing IL-10 in the cultures after recall with the
indicated recombinant factors. Data are represented as Whisker (min to max) plots. Asterisks show the statistical differences between the data of the stimulated and
the non-stimulated cultures (Kruskal–Wallis test).
vesicles (Silverman et al., 2008; Cuervo et al., 2009; Torrecilhas
et al., 2012) may be also an alternative form of presentation of
those antigens to the host immune system, since Leishmania is
able to release microvesicles in the mammalian host (Silverman
and Reiner, 2012) and their contents have been found to induce
humoral responses in murine susceptible hosts (Hernández-
Chinea, 2007), canine (Lima et al., 2016), and human patients
(Soares et al., 2015) as well as inhibitory signaling for dendritic
cells activation (Markikou-Ouni et al., 2015; Iborra et al., 2016;
von Stebut and Tenzer, 2018). Interestingly, whereas in patients
with the active form of the disease they induce strong humoral
responses (Requena et al., 2000a; Maalej et al., 2003; Rafati et al.,
2007; Costa et al., 2012; Souza et al., 2013) as well as IL-10
mediated responses (Bottrel et al., 2001; de Carvalho et al., 2003;
Antonelli et al., 2004; Carvalho et al., 2005) in asymptomatic or in
cured patients these proteins usually induce Th1-like responses
(Probst et al., 2001; Bourreau et al., 2003; Baharia et al., 2014;
Jaiswal et al., 2014; Cecilio et al., 2017). For this reason, these
proteins are considered adequate humoral and cellular markers
of infection, and the immune response elicited against them can
be useful employed to monitor the development of the infection
and also the success of the treatments.
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A limitation of this work is that we have not tested cellular
samples from natural leishmaniasis patients to analyze the
cellular responses elicited against both factors. However, as an
alternative, we moved onto murine models of leishmaniasis in
order to understand the relationships of the parasite LieIF2 and
LieIF2B and the host cellular immune system. First we found that
these factors are also antigenic in mice infected with L. infantum
(BALB/c) or L. major (BALB/c and C57BL/6) (Table 3). As it is
deduced from data included in the Figure 2 and Supplementary
Figure 4, the quality of the anti-LieIF2 or anti-LieIF2B humoral
response was qualitatively similar to that observed for SLA,
although with a lower intensity. The humoral response against
the translation factors in the L. infantum infected BALB/c showed
the mixed IgG1/IgG2a pattern found in this VL model against
SLA, concomitant to the chronic infection in the spleen and
the active destruction in the liver conducted by a parasite-
specific T-cell dependent macrophage activation (Engwerda and
Kaye, 2000; Garg and Dube, 2006; Loría-Cervera and Andrade-
Narváez, 2014; Sacks and Melby, 2015). In the highly susceptible
BALB/c-L. major model we found a predominant IgG1 antibody
response against both factors, associated with the SLA-dependent
Th2 response typically found in this mouse strain. In the resistant
model C57BL/6-L. major, the low reactivity found against the
factors was associated with the induction of IgG2c antibodies
related to the generation of protective Th1-mediated responses
(Sacks and Noben-Trauth, 2002; Sacks and Melby, 2015). The
patterns of LieIF2- and LieIF2B-driven production of IFN-γ
fits well with the different evolution of the disease in the three
distinct murine models. Although in all cases production of this
inflammatory cytokine is limited, there is a greater tendency for
its secretion by cells from the C57BL/6 mice resistant to CL and
in the BALB/c VL, where parasites are eliminated in the liver
(Figure 3). On the other hand, the L. major infected susceptible
animals were unable to produce LieIF2 and LieIF2B-dependent
IFN-γ (Figure 3). Of note, a predominance of LieIF2 and LieIF2B
factors-mediated IL-10 production was observed in the three
experimental models of murine leishmaniasis regardless clinical
evolution (Figure 3). This down-regulatory cytokine has been
related to disease progression in mice models of CL (Noben-
Trauth et al., 2003; Ronet et al., 2010; Buxbaum, 2015; Lee et al.,
2017) or VL (Murphy et al., 2001; Faleiro et al., 2016) and in
human CL or VL patients (Nylén et al., 2007; Carvalho et al.,
2012, 2015; Gollob et al., 2014; Nabavi et al., 2018). Parasite
proteins implicated in IL-10 production are being considered
virulence factors and markers of disease. This is the case of the
parasite KMP-11, a surface located protein that is implicated in
the stimulation of IL-10 production by patients affected by CL
and also in cultured murine macrophages infected in vitro by
L. amazonensis (de Carvalho et al., 2003; de Mendonça et al.,
2015). Similarly, the recombinant version of the papLe22 antigen
is able to induce IL-10 secretion in human patients affected by
VL (Suffia et al., 2000). In this work, we have found that the
LieIF2- and LieIF2B-related IL-10 production occurred in the
three murine models tested, although was higher in magnitude
in the CL models (Figure 3). The immunological consequences
of this production may be different. It has been previously
reported that deficiency in IL-10 does not alter the final healing
phenotype after L. major challenge in C57BL/6 mice (Schwarz
et al., 2013). On the other hand, IL-10 plays a major role in CL
disease evolution of BALB/cmice, as demonstrated by the healing
phenotype shown by IL-10 deficient mice (Schwarz et al., 2013)
or in the murine VL disease (Murphy et al., 2001). The fact that
some of the subunits of the LieIF2 and LieIF2B factors are able
to induce the secretion of IL-10 in spleen cells from both BALB/c
or C57BL/6 naïve mice could be reinforcing the idea that these
factors can be considered virulence factors. As mentioned above,
the generation of early humoral responses to them is evidence
of their rapid presentation to host B lymphocytes, cells that are
also involved in the development of the disease throughout IL-
10 production (Andreani et al., 2015; Silva-Barrios et al., 2017).
The ability of the factors to induce the secretion of IL-10 in
these cells would contribute to generate an anti-inflammatory
environment in the infected tissues that would facilitate the
progression of the parasite. A similar comportment has been
postulated for the parasite cytosolic tryparedoxin, since it has
been implicated in the induction of IL-10 by B cells of naïve
mice (Cabral et al., 2008). The exposure of these intracellular
Leishmania proteins may participate in immune-pathological
processes by targeting B-cell to produce specific antibodies and
leading to IL-10 secretion. The effect may be similar to the
exposure to sand fly saliva factors that, by up-modulating IL-
10 production enhance Leishmania infection in mice infected
with cutaneous-tropic species (Norsworthy et al., 2004) or in
human patients (Carvalho et al., 2012, 2015; Gollob et al., 2014).
Data obtained in this work reinforce the implication of different
parasite proteins in the modulation of the host immune system in
order to facilitate the progress of infection. Previously reported
examples are the LACK protein, a homolog of the receptor
for activated C kinase in mammalian cells, which mounts an
early IL-4 response after Leishmania infection (Launois et al.,
1997) or some parasite secreted antigens that modulate C57BL/6
immune system toward a Th2 response (Tabatabaee et al., 2011).
Also, the ribosomal protein S3a was found to be implicated
in the induction of polyclonal expansion of B cells beside the
inhibition of T cell proliferative responses (Cordeiro-Da-Silva
et al., 2001).
Modulating the response against some of these
immunologically active proteins by their administration in
combination with adequate adjuvants was postulated as an
interesting field of research for development of prophylactic or
therapeutic vaccines (Badaro et al., 2001; Duarte et al., 2016b;
Reguera et al., 2016). As a proof of concept, the inoculation
of parasite ribosomal proteins combined with un-methylated
CpG motives [ligands for the pro-inflammatory TLR-9 (Reed
et al., 2013)] resulted in the protection against L. major infection
inducing IFN-γ-mediated responses in C57BL/6 or BALB/c
mice, correlated to the control of the humoral responses and
IL-10 production driven by these parasite antigens in the last
model (Iborra et al., 2008). In this work, as a proof of concept
we tested DNA-vaccines based on both factors, taking advantage
of the capacity of these genetic vaccines to induce IFN-γ
mediated cellular responses specific for the proteins encoded
in the plasmid vectors (Kaur et al., 2016; Kumar and Samant,
2016; Maspi et al., 2017). Our data showed that the LieIF2
and LieIF2B vaccinated mice produced IFN-γ in response to
the corresponding subunits of both factors. However we also
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detected a LieIF2- and LieIF2B-specific production of IL-10
following immunization (Figures 5–8). In agreement with the
results obtained in this work, the incapacity to control IL-4 or
IL-10 production beside the induction of IFN-γ was considered
as a bad marker for protection (Roberts et al., 2005) as it has been
correlated with the inability to generate protective responses in
BALB/c mice against L. major (Sjölander et al., 1998; Iborra et al.,
2005, 2007) or L. infantum (Pirdel et al., 2014). The failure in
protection showed in this work for the BALB/c CL model may
be related to the necessity to control the responses mediated by
IL-4 and by IL-10 besides generating IFN-γ as occurred with
other tested vaccines against the parasite in CL (Gomes et al.,
2012; Soto et al., 2015; Duarte et al., 2017) or VL models (Goto
et al., 2011; Martins et al., 2017). On the other hand, protection
in the C57BL/6-L. major model was associated to the induction
of rapid IFN-γ mediated responses after infective challenge
rather than the control of Th2 or IL-10 mediated responses
as occurred with different vaccines based on parasite antigens
or Leishmania live vaccines (Iborra et al., 2005; Kébaïer et al.,
2006; Doroud et al., 2011; Peters et al., 2012; Solana et al., 2017).
In this sense, the appearance of less severe lesions in C57BL/6
vaccinated mice after L. major infective challenge allows to
reinforce the conclusion that both factors play a prominent role
in the immune response after Leishmania infection.
We conclude that the subunits forming LieIF2 and LieIF2B
factors are able to interact with the host immune system
during Leishmania infection in different mammalian hosts. The
induction of antibodies against the different subunits allows their
classification as humoral markers of the disease. In addition,
our findings related to the LieIF2 and LieIF2B production of
IL-10 in mice infected with L. major also highlight the role of
these factors as cellular markers of the disease and link them
with the promotion of susceptibility against leishmaniasis. Since
some of the LieIF2 and LieIF2B subunits are able to induce
the secretion of IL-10 in B cells from naïve mice, they may
be considered virulence factors implicated in the induction of
early down-regulatory immune responses that may facilitate the
progression of the infection. The induction of partial protective
responses in C57BL/6 by the administration of LieIF2 or LieIF2B-
based DNA vaccines opens the possibility of designing new
formulations combining different subunits and adjuvants or
new forms of antigen delivery to improve their prophylactic
capacities.
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